Clinical Research Directory

Key Inclusion Criteria: * Documented NDMM according to IMWG diagnostic criteria * Considered to be transplant-eligible by the investigator * Measurable disease at screening per IMWG, defined as any of the following: 1. Serum M-protein level ≥ 1.0 g/dL; or 2. Urine M-protein level ≥ 200 mg/24 hours; or 3. Serum free light chain (FLC) ≥ 10 mg/dL (100 mg/L) and abnormal serum FLC ratio * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ function including hematological, renal, hepatic and cardiac with further details in protocol defined inclusion/exclusion criteria Key Exclusion Criteria: * Any prior anti-multiple myeloma (MM) therapy (including B-cell maturation antigen (BCMA)-directed therapy, CAR T-cell therapy, or genetically modified cells), with the exception of protocol-specified anti-MM stabilizing therapy, radiotherapy for MM plasmacytoma(s), and palliative focal radiation * Central nervous system (CNS) or meningeal involvement of MM * Cardiac atrial or ventricular MM involvement * History of or active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis * Active malignancy (other than MM) requiring treatment for disease control within the last 24 months. * Prior allogeneic stem cell transplant * Any prior systemic treatment or radiotherapy treatment for any cancer other than MM within 24 months before randomization. * Live vaccine ≤ 4 weeks before randomization * Presence or suspicion of infection that is uncontrolled * History or presence of intracranial or CNS disorders or malignant CNS neoplasms * Females who are pregnant or breastfeeding * Females of childbearing potential who are not willing to use a highly effective method of contraception from the time of informed consent through the protocol-specified duration. * Contraindication to fludarabine, cyclophosphamide, or melphalan * History of allergy or hypersensitivity to any trial agent or trial drug components * Life expectancy \< 12 weeks Note: Other protocol defined Inclusion/Exclusion criteria may apply.